Target intelligence / Profile preview

Troponin C1, slow skeletal and cardiac type (TNNC1)

Target
TNNC1
Molecular classification
EF-hand calcium-binding protein, contractile protein complex component
01

Overview

Troponin C1, slow skeletal and cardiac type (TNNC1) encodes a calcium-binding regulatory protein crucial for striated muscle contraction, specifically in cardiac and slow-twitch skeletal muscle[1][4]. It forms part of the troponin complex, together with troponin I and troponin T, on the actin filament. Troponin C's core function is to sense and bind calcium ions via its EF-hand motifs—calcium binding induces structural changes that release inhibitory constraints on actin-myosin interaction, thereby triggering muscle contraction[2][3][4]. TNNC1 is implicated in the pathogenesis of both familial dilated and hypertrophic cardiomyopathy when mutated[1][2][4]. Drugs that interact with or modulate TNNC1 (e.g., calcium sensitizers like levosimendan) are being developed to treat certain cardiac diseases by enhancing myocardial contractility without increasing intracellular calcium load[2]. This protein is highly conserved, and its proper regulation is essential for coordinated heartbeat and skeletal muscle contraction[2][3].

Other names
Troponin C, slow skeletal and cardiac musclesTNNC1TNNCTnCTN-CCMD1ZCMH13cardiac troponin Cslow twitch skeletal/cardiac muscle troponin Ctroponin C type 1 (slow)
02

Mechanism of action

Calcium sensitization (drugs like levosimendan increase calcium sensitivity of cTnC, enhancing contractility)[2]; modulation of calcium binding affinity (affecting troponin conformation and thus muscle contraction)[2]

03

Biological functions

Muscle contraction regulationcalcium signalingactin-myosin interactioncardiac and skeletal muscle contraction
04

Disease associations

Cardiovascular diseaseCardiomyopathy (dilated, familial hypertrophic)
05

Safety considerations

Targeting troponin C risks dysfunctional contractility leading to arrhythmias or heart failurealtered calcium sensitivity can exacerbate or ameliorate heart failure symptoms depending on context[2]
06

Interacting drugs

Levosimendan (calcium sensitizer)[2]

1 more in the full profile.

07

Biomarkers

Cardiac troponin C is not as widely used as cardiac troponin I or T for routine myocardial infarction diagnosis, but altered levels or mutations can serve as biomarkers in familial cardiomyopathies[2][4]

Beyond the preview

Go deeper on Troponin C1, slow skeletal and cardiac type (TNNC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Troponin C1, slow skeletal and cardiac type (TNNC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call